3-day Virtual Seminar

AI in Pharmacovigilance

Overview

This webinar provides a broader look at how artificial intelligence is beginning to influence pharmacovigilance. It considers the expanding role of AI across safety information management and the ways generative AI may support knowledge-based work such as organising information, summarising appropriate material, assisting with internal research and helping professionals navigate large volumes of safety-related content.

The session also addresses the questions that become more important as AI use expands: How reliable is the output? What source information supports it? Could relevant context have been missed? Is sensitive information being handled appropriately? What level of review is proportionate to the task?

Attendees will also gain awareness of the direction regulators are taking on AI in pharmacovigilance, helping them understand why human-centric design, data governance, context of use, performance assessment and lifecycle management are becoming increasingly important concepts for regulated AI adoption.

Why you should Attend

Pharmacovigilance teams cannot treat AI output as automatically reliable simply because it is fast or convincing. Safety information can be nuanced, incomplete or dependent on context, while generative AI can omit details, make unsupported connections or produce inaccurate information with confidence.

As regulators themselves explore AI-supported pharmacovigilance, professionals need to understand both sides of the opportunity: what AI may help them do more efficiently and what must remain under robust human and procedural control. This webinar provides that balanced foundation before AI becomes further embedded in safety workflows.

Areas Covered in the Session

• Understand the growing role of AI across the medicines lifecycle and why pharmacovigilance is receiving specific regulatory attention
  
• Explore where AI and generative AI may support information processing, knowledge retrieval and productivity within pharmacovigilance
  
• Consider how AI can assist with organising and summarising suitable safety-related information while preserving the underlying context
  
• Recognise limitations including hallucinations, incomplete information, bias and apparently credible outputs that may not be supported by evidence
  
• Understand why context of use and the potential impact of an AI-supported activity should influence the level of control and review applied
  
• Apply source verification, critical thinking and human oversight when AI contributes to pharmacovigilance-related work
  
• Consider data governance, confidentiality, quality and documentation when AI systems interact with safety information
  
• Understand current regulatory direction, including international collaboration on AI in pharmacovigilance and emerging guidance activity
  
• Recognise that responsible AI adoption requires ongoing monitoring and governance rather than a one-time decision to approve a tool
  

Who Will Benefit

• Pharmacovigilance and Drug Safety Professionals
  
• Safety Scientists and Safety Managers
  
• Pharmacovigilance Operations Professionals
  
• Benefit-Risk and Safety Surveillance Teams
  
• Pharmacovigilance Quality and Compliance Professionals
  
• Regulatory Affairs Professionals
  
• Medical Information and Safety Support Teams
  
• CRO Pharmacovigilance Professionals
  
• Life Sciences Leaders responsible for AI, digital transformation or safety operations